衰老和神经退行:从分子机制到治疗干预
Tiago Fleming Outeiro1,2,3,4, Patricia S Brocardo5, Daniel P Gelain6
1Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Gottingen, Göttingen, Germany.
Journal of neurochemistry
|June 26, 2024
概括
蛋白质聚合是神经退行性疾病的标志,由与衰老相关的细胞蛋白质稳定性下降驱动. 了解这些分子驱动因素对于开发有效的治疗干预措施至关重要.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 蛋白质聚合是衰老和神经退行性疾病的共同标志.
- 与年龄相关的蛋白质稳定网络活性下降有助于蛋白质聚合.
- 在特定细胞类型中蛋白质聚合的分子驱动因素仍然不太清楚.
研究的目的:
- 推出一个专题专注于衰老和神经退行症的专题.
- 评估衰老细胞中的病理驱动因素.
- 探索神经退行性疾病的分子机制和治疗干预措施.
主要方法:
- 审查当前关于衰老和神经退行症的研究.
- 评估细胞病理背后的分子机制.
- 确定导致老化细胞神经退行的主要因素.
主要成果:
- 蛋白质聚合与衰老和神经退行有关.
- 蛋白质稳定网络的衰退是一个重要的因素.
- 氧化应激,糖化和线粒体损伤是关键的病理驱动因素.
结论:
- 为了开发治疗方法,需要对分子机制进行进一步的研究.
- 针对与年龄相关的细胞功能障碍提供了治疗潜力.
- 本专题提供了从分子到治疗层面的老化和神经退行现象的见解.
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Aging
41
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
41
Alzheimer's Disease: Treatment
178
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
178
Parkinson's Disease: Overview
523
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
523
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K


